Nepicastat hydrochloride is a potent and selective dopamine β-hydroxylase inhibitor used in cardiovascular therapy for heart failure caused by ventricular dysfunction; it prevents left ventricular dysfunction and remodeling in dogs with chronic heart failure, and shows additional therapeutic benefits when combined with enalapril; it also reduces norepinephrine levels, increases dopamine levels and the dopamine/norepinephrine ratio in tissues, and exhibits antihypertensive effects by decreasing renal vascular resistance and increasing renal blood flow; additionally, it attenuates cocaine-induced reinstatement of drug-seeking behavior in rats.